

Policy Title: Lobular Carcinoma In Situ (LCIS) & Equivocal Diagnosis for Breast Cancer	
Section: Eligibility	Reference No. SB 070
Effective: February 1993	Revision: January 2018

1. SCOPE

All Breast Screening Centre Staff
Client Services Centre Staff

2. POLICY

Lobular Carcinoma in Situ (LCIS)

- Women with a previous diagnosis of atypical lobular hyperplasia (LIN 1) or (LIN 2) lobular carcinoma in situ are eligible to participate in the Breast Screening program.
- Since LCIS is a marker for predisposition to develop breast cancer rather than an actual precursor lesion such as ductal carcinoma in situ, the BC Cancer Breast Tumour Group recommends that patients with LCIS be eligible to attend screening.

Equivocal Diagnosis for Breast Cancer

- Women with equivocal (uncertain) diagnosis for breast cancer at biopsies are eligible to participate in the program.
- The BC Cancer Breast Tumour Group recommends that patients with equivocal diagnosis for breast cancer be eligible to attend screening.

Women with questions about these diagnoses should be referred to their family physicians.

3. RELATED POLICIES

4. RESPONSIBLE PARTY

Breast Screening Medical Director